Tagged with CAR-T

Hong Kong With Hong Kong now host to a growing volume of public and private entities specializing in cell and gene therapy development, some market insiders spy great opportunities for the city, with its unique background context and characteristics, to play a role shaping the next wave of biomedicine discovery.   Dr…

Hong Kong In summer 2023, Hong Kong entered the next frontier of cancer care with the launch of its first hospital-based CAR-T clinical trial. Developed entirely within city limits by a team of clinicians and scientists at the Chinese University of Hong Kong (CUHK), Prince of Wales Hospital, and the Hong Kong…

Hong Kong Few biotech companies emerge with both scientific depth and a clear sense of direction. Innorna, founded by Dr Linxian Li after years spent refining RNA delivery systems in academic settings, is one of them. What began as a technical platform matured through a pandemic-era proof of concept and now moves…

Hong Kong At the Centre for Oncology and Immunology, a flagship of Hong Kong’s Health@InnoHK initiative, science converges across disciplines and continents. Under the leadership of Professor Tak Wah Mak, the Centre is advancing a new understanding of how immune responses are shaped, not only by tumours, but by the nervous system…

Hong Kong With Asia-Pacific poised to become a global force in cell and gene therapy, Xellera Therapeutics is positioning itself at the heart of this transformation. Led by CEO Camie Chan, the Hong Kong-based company is bridging critical infrastructure gaps by offering GMP-certified manufacturing, regulatory compliance aligned with global standards, and a…

Hong Kong Professor Guangjin Pan, Managing Director of the Centre for Regenerative Medicine and Health (CRMH), discusses how the center’s focuses on translating cutting-edge science into clinical and commercial success – driving Hong Kong’s ambition to become a global biotech hub. As Part of the Hong Kong Institute of Science & Innovation…

Hong Kong A long-standing figure in Hong Kong’s haematology landscape, Professor Kenny Lei has played a pivotal role in advancing lymphoma care and cellular therapies over the past three decades. His contributions span the early adoption of autologous peripheral blood stem cell transplantation and active involvement in establishing the city’s first hospital-based…

Hong Kong In recent years, the Hong Kong Institute of Biotechnology (HKIB) has entered a new phase, shifting from the groundwork of facility-building to the clinical delivery of locally manufactured CAR-T therapies. Managing Director Gina Jiang reflects on this transition and shares how early operational lessons are in forming a wider platform…

Hong Kong In our field, success is not defined by short-term remission alone, but by long-term disease eradication. Our goal is always a cure, not prolonged management. After decades spent advancing paediatric oncology in Hong Kong, Professor Li Chi Kong has increased his focus toward the frontier of cell and gene therapies, spearheading…

Hong Kong For anyone seeking a place where world-class science and a balanced lifestyle can coexist, Hong Kong offers a uniquely compelling proposition. As China’s pharmaceutical landscape expands into innovative biologics, SPH Biotherapeutics (HK) – an R&D affiliate of Shanghai Pharma – is advancing a dual-targeting CAR-T platform with early clinical results…

Switzerland Lars Nieba PhD, CEO of Engimmune, shares insights into the company’s innovative approach to T-cell therapies and its strategic direction as it prepares for its Series A funding round. Nieba discusses the promising therapeutic areas Engimmune is targeting—particularly liver cancer and immunology—and the company’s unique technology that harnesses soluble T-cell…

China Chinese player Legend Biotech reached a new turning point last month when its Johnson & Johnson-partnered Carvykti became the first BCMA-targeted CAR-T cell therapy to be approved by the FDA for second-line treatment of multiple myeloma. From its original roots in China to its first FDA approval in 2022, the…